## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Rachael ANCLIFF et al. Conf. No. 5647
Serial No.: 10/531,758 Art Unit: 1624

Filing Date: April 14, 2005 Examiner: Coleman, Brenda Libby

For: Substituted Piperazines, (1,4) Diaszepines, and 2,5-Diazabicyclo (2.2.1) Heptaines as Histamine H1 and/or H3 Antagonists or Histamine H3 Reverse Antagonists

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[X] Copies of the references are enclosed  [ ] Copies of the references were submitted in parent application Serial No								
		(37 CFR 1.98(d))							
	[ ] A copy of the International Search Report which issued on International Application No is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.								
	344	spinor to the O.S. Patent Office by the international Duleau.							
A.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).							
	OR	• •							
	The Information Disclosure Statement submitted herewith is being filed before mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).								
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  (1) a final action under § 1.113 or  (2) a notice of allowance under § 1.311, whichever occurs first.							
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.							
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).							

## Atty. Docket No. P33126USw

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action
		under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the
		payment of the issue fee. Also enclosed is a copy of the International Search Report which
		Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [ ] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [ ] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No. 07-1392.

[ ] A duplicate copy of this paper is attached.

Respectfully Submitted,

James P. Riek

Attorney of Record Registration No. 39,009

Date: 11-15-2006

Customer No. 23347 GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8022 Facsimile: (919) 483-7988

FORM PTO	)-1449	)			SERIAL NO.		10/531,75	58			
INFORMA	TION	DISCLOSURE ST	ATEMENT		FILING DATE		April 14, 2005				
					APPLICANT GROUP		Rachael Anciliff et al.				
							1624				
					EXAMINER		Coleman	Coleman, Brenda Libby			
					ATTORNEY DOCKET NO.		P33126USw				
U.S. PATENT DOCUMENTS											
Filing Dat											
Examiner Initiak		Patent Number	Issue Date		Name	Class	Subclass	If Appropriate			
	1.	5,880,128	03/1999	DOLL et	al.						
			j								
						<del>                                     </del>					
						<del>                                     </del>		<del>                                     </del>			
-	Ī					<del>                                     </del>					
·				†		<del>  </del>					
	1			<del>†</del>		<del>                                     </del>					
_	<u>.                                    </u>		<u> </u>	Continue on p	1200	11					
			FORFIC	N PATEN	F DOCUMENTS						
	1	Document	Publication	HIAILA	DOCUMENTS	т т		Translation			
	1	Number	Date	1 .	Country	Class	Subclass	Yes   No			
	2.	DE 4410822	09/1995	DE	Country	C1833	Suociass	·			
<u> </u>	3.	WO 95/25443	09/1995	PCT		┼		X			
	4.	WO 97/26252	07/1997	PCT		+		X			
	5.	WO 99/41242	08/1999	PCT		<del>                                     </del>		X			
	6.	JP 2002-173426	06/2002	JP	<del></del>	<del>                                     </del>		X			
	7.	WO 04/094441				<u> </u>		Х			
	<del>  '-</del>	MO 04/034441	11/2004	PCT				X			
	<del> </del>	<del>-</del>									
	<u> </u>	<del>-</del>		ļ <u></u>							
	<u> </u>			<u></u>							
				ontinue on p							
		OTHER DOCUM	<u>IENTS (Includi</u>	ng Author,	Title, Journal-Da	te, Page Num	ber, Etc.)				
	<b>↓</b>										
	<b>↓</b>										
	╄										
	₩										
	<u> </u>										
		<u> </u>									
							·				
					<u> </u>						
				ontinue on	page						
EXAMINER		DATE	ATE CONSIDERED								
			_								
EXAMINER citation if no	: Initia t in cor	al if citation consident formance and not c	red, whether or possidered. Inch	not citation i	s in conformance w	with MPEP § 6	09; Draw line	through			